NPCE · XBRL financial data

NeuroPace financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (NPCE's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	45,183	45,520	65,421	79,906	99,986
Cost of goods and services sold	11,748	13,027	17,299	20,821	22,766
Gross profit	33,435	32,493	48,122	59,085	77,220
Research and development	18,211	21,946	20,778	23,653	27,888
Selling, general and administrative	38,961	51,341	54,518	57,103	—
General and administrative	—	—	—	17,434	19,090
Total operating expenses	57,172	73,287	75,296	80,756	93,558
Operating income (loss)	(23,737)	(40,794)	(27,174)	(21,671)	(16,338)
Interest income	448	1,578	3,050	3,024	2,816
Interest expense	7,410	7,529	8,517	8,798	7,457
Other income (expense)	(5,381)	(337)	(315)	304	(486)
Income tax expense (benefit)	—	—	—	—	0
Net income (loss)	(36,080)	(47,082)	(32,956)	(27,141)	(21,465)
Earnings per share, basic USD per share	(2.17)	(1.91)	(1.27)	(0.93)	(0.66)
Earnings per share, diluted USD per share	(2.17)	(1.91)	(1.27)	(0.93)	(0.66)
Weighted average shares, basic thousands of shares	16,609	24,595	25,852	29,126	32,722
Weighted average shares, diluted thousands of shares	16,609	24,595	25,852	29,126	32,722

Fiscal years (NPCE's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	19,187	6,605	18,058	13,430	21,692
Short-term investments	96,397	70,804	48,396	39,325	39,366
Marketable securities	96,397	—	—	—	—
Accounts receivable	7,091	7,482	12,314	12,851	14,681
Inventory	7,822	9,712	11,214	13,381	16,896
Prepaid and other current assets	2,319	3,111	2,737	2,352	1,438
Total current assets	132,816	97,714	92,719	81,339	94,073
Property and equipment, net	603	1,064	1,003	1,052	1,125
Right-of-use asset	0	14,838	13,405	11,843	10,132
Total assets	133,562	114,106	107,651	94,647	105,565
Accounts payable	1,378	2,147	2,332	2,954	2,217
Accrued liabilities	7,923	7,414	11,180	9,787	13,339
Current portion of long-term debt	0	—	—	—	—
Total current liabilities	9,301	10,976	16,229	15,156	17,814
Long-term debt	49,847	52,913	56,954	59,525	58,884
Lease liability, non-current	0	15,440	13,814	11,953	9,836
Total liabilities	60,059	79,329	86,997	86,634	86,534
Accumulated deficit	(423,771)	(470,853)	(503,809)	(530,950)	(552,415)
Total stockholders' equity	73,503	34,777	20,654	8,013	19,031
Total liabilities and equity	133,562	114,106	107,651	94,647	105,565
Common shares outstanding (cover page) thousands of shares	24,471	25,099	28,345	32,560	33,667

Fiscal years (NPCE's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(36,080)	(47,082)	(32,956)	(27,141)	(21,465)
Stock-based compensation	4,288	8,349	9,558	10,282	11,089
Net cash from operating activities	(24,577)	(36,869)	(19,701)	(17,949)	(11,006)
Purchases of property and equipment	384	603	173	306	332
Net cash from investing activities	(85,396)	23,797	23,027	8,994	(332)
Share repurchases	—	—	—	0	49,546
Net cash from financing activities	102,526	490	8,127	4,327	19,600
Net change in cash	(7,447)	(12,582)	11,453	(4,628)	8,262

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
NeuroPace	12,538	22,826	(3,903)*	34.3M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
ClearPoint Neuro	46,184	12,075	(20,100)	32.1M	6.6 quarters	Q3 FY26 10-QSep 30, 2026
Outset Medical	35,005	31,635	(9,635)*	18.8M	15.3 quarters	Q2 FY26 10-QJun 30, 2026
SS Innovations International	13,647	not reported	(4,235)*	200.4M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
EBR Systems	59,350	2,637	(17,194)*	75.3M	5.0 quarters	Q2 FY26 10-QJun 30, 2026
Treace Medical Concepts	12,610	45,376	(4,698)*	65.0M	9.7 quarters	Q2 FY26 10-QJun 30, 2026
Bioventus	30,709	142,442	20,658*	not reported	—	Q3 FY26 10-QSep 26, 2026
Orthopediatrics	17,141	72,661	4,506*	26.1M	—	Q3 FY26 10-QSep 30, 2026
Carlsmed	46,244	not reported	(7,358)*	27.3M	9.5 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.